The UK and US have forged a important bilateral deal that will ensure zero levies on British drug products entering the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has pledged to raise funding on pharmaceuticals through the public health system. This commitment secures that import taxes on these key products will be held at zero for a timeframe of 36 months.
This deal follows recent statements to dramatically increase import taxes on branded drug imports, with increases discussed up to 100%.
"This agreement with the UK bolsters the worldwide climate for cutting-edge drugs and brings much-needed fairness to U.S.–U.K. medicine commerce," a release declared.
Economic Importance
Pharmaceuticals constitute one of the the United Kingdom's biggest exports to the US, which is clearly the primary buyer for major UK drugmakers.
Export figures show that in the one-year period leading up to the third quarter, the UK shipped drugs totaling £11.1bn to the US. This figure represented a significant portion of British export trade in that period.
"This guarantee secures employment, increases funding and sets the stage for the UK to emerge as a worldwide center for medical research," a minister remarked.
Specific NHS Changes
The agreement includes several specific changes from the United Kingdom:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it considers new therapies to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a aim to double total NHS spending on treatments from 0.3 percent of the national economy to 0.6% over the next decade.
- Refund Ceiling: The sum manufacturers must pay back to the NHS to control costs will be restricted at fifteen percent. Last year, repayments exceeded twenty percent.
Industry Background
The pact takes place against a protracted row between the sector and the British authorities over medicine costs and NHS adoption.
These tensions were intensified by assertions that American customers were paying significantly more for the equivalent treatments than people in the UK and Europe.
In recent months, several major drug company projects in the UK have been halted or cancelled, while multi-billion-dollar expansions have been pledged toward American operations.
The Science Minister stated that the NHS must spend more on treatments, noting that its budget allocation on drugs had declined as a percentage of its total funding over the previous ten-year period.